Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis.

Next Previous
Trial Profile

ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary) ; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis; Myocardial reperfusion injury
  • Focus Biomarker; Therapeutic Use
  • Acronyms ROMA

Most Recent Events

  • 25 Oct 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
  • 25 Oct 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
  • 25 Oct 2010 Actual initiation date (March 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top